Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. GNPX
G

Genprex, Inc. (GNPX)

1.82

0.00 (0.00%)

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
1.82$
Day's range
1.81 - 1.89$
52-week range
1.71 - 55$
Volume
185 644
Average volume
300 015
Beta
-0.31
EPS (TTM)
-47.66
PE ratio (TTM)
N/A
Market cap
4 220 387
Shares outstanding
2 318 894
Dividend yield
N/A
Next earnings date
2026-06-03
Sector
Healthcare
Industry
Biotechnology

About the company

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanop... read more
CEO
Ryan Confer
Country
United States
IPO Date
2018-03-29
Employees
13
Fiscal Year End
January - December
Website
https://www.genprex.com

Revenue Breakdown

No Data

Revenue breakdown data has not been calculated yet.

News

No Data

There are no news for this stock.

Chart: GNPX

Loading Chart...

Overall Score

2.5 / 1025%
Financial Strength
5.8
Profitability
1
Effectiveness
1
Growth
4.8
Forecast
1.6
Valuation
3.8

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio0.676.054.0
Quick ratio0.675.634.0
Debt to Equity0.000.3010
Debt to Assets0.001.0410
Interest coverageN/A-16.911.0
Weighted average score5.8

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2021202220232024TTM
Total RevenueN/AN/AN/AN/AN/A
Gross Profit-23K-26K-15K-7K-463
Operating Income-21M-24M-31M-21M-16M
Net Income-21M-24M-31M-21M-17M
EBITDA-21M-24M-31M-21M-16M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %N/A-11.731.0
Operating margin %N/A-24.601.0
Net margin %N/A-172.201.0
EBITDA margin %N/A-201.271.0
Cash flow margin %N/A-156.391.0
Weighted average score1.0

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA-317.87-57.97
1.0
ROE-687.79-63.56
1.0
ROIC-687.79-42.57
1.0
ROCE-259.44-71.10
1.0
Weighted average score1.0

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarterN/AN/A1.0
Next quarterN/AN/A1.0
Current yearN/AN/A1.0
Next yearN/A83.5
Weighted average score1.6

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q99918.73N/A17.527.3
Y/Y99911.97N/A-45.84.8
3y average999-4.41-15.91N/A3.3
5y average999-19.352.1-42.483.8
Weighted average score4.8

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/E0.08-5.25
10
PEG (5yr expected)N/A0.27
1.0
P/SN/A64.66
1.0
P/B5.562.96
3.2
Weighted average score3.8

DCF Model

DCF Model PeriodN/A
Discount rateN/A
Perpetual growth rateN/A
Revenue 5 year CAGRN/A
FCF 5 year CAGRN/A
Fair value$
Stock price1.82$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$1

UndervaluedStock priceOvervalued

$1.82

Economic Moat

NAMESCALESCORE
Market shareNone1.0
Intangible assetsNone1.0
Switching costsNone1.0
Network effectNone1.0
Economies of scaleNone1.0
Weighted average score1.0
Dividend
1
Economic Moat
1

Octagon View

Strength & Weakness

Cash reserves $1.1M barely cover the upcoming debt maturities $0.0

Total current liabilities $2.6M surpass Total current assets $1.7M, signaling liquidity issues

Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage

Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns

Negative free cash flow -$3.2M limits the company's ability to reinvest or pay down debt